Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 7/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860009 | 0.91 | MEN1 (0.48) | LMNAGAAMEN1KMT2ARAB9A | |
| SCHEMBL3974760 | 0.90 | LMNA (0.47) | LMNAGAAMEN1KMT2ARAB9A | |
| SCHEMBL3979286 | 0.85 | LMNA (0.51) | LMNAGAAMEN1KMT2ARAB9A | |
| SCHEMBL3973035 | 0.85 | MAPK14 (0.44) | GAAMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3974678 | 0.85 | MAPK14 (0.44) | MAPK13MAPK12MAPK11MAPK14GRN | |
| SCHEMBL5005267 | 0.84 | MAPK14 (0.53) | LMNAMEN1KMT2AMAPTMAPK13 | |
| SCHEMBL3864390 | 0.83 | MAPK14 (0.48) | MAPK13MAPK12MAPK11MAPK14GRN | |
| SCHEMBL3864506 | 0.83 | MAPK14 (0.48) | LMNAGAAMEN1KMT2ARAB9A | |
| SCHEMBL3978605 | 0.83 | DHODH (0.46) | LMNAGAAMEN1KMT2ARAB9A | |
| SCHEMBL3972382 | 0.82 | MEN1 (0.46) | LMNAGAAMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | claimed |
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-01 | — | — | US | claimed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | GPR119, GOT2, IAPP | LMNA 3423/4885GAA 369/4885MEN1 3766/4885 |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | GPR119, GOT2, IAPP | LMNA 3423/4885GAA 369/4885MEN1 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.